Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Ter Arkh ; 95(6): 475-480, 2023 Aug 17.
Article in Russian | MEDLINE | ID: mdl-38158966

ABSTRACT

AIM: To compare changes in the complement system in C3-glomerulopathy (C3-GP) and atypical hemolytic uremic syndrome (aHUS) after the relief of an acute episode of thrombotic microangiopathy. MATERIALS AND METHODS: The study included 8 patients diagnosed with C3-GP and 8 with aHUS in remission. The blood levels of the complement system components were determined: C3, C4, C3a, C5a, factor H (CFH), factor B (CFB), membrane-attacking complex (MAC), antibodies to C3b (anti-C3b-AT), the level of hemolytic activity (CH50), the content of factor D (CFD) in the urine. RESULTS: C3 and CH50 levels were within the reference range in both groups, however, in the C3-GP group they were at the lower limit, and C3 level was significantly lower than in the aHUS group: 0.56 [0.44; 0.96] vs 1.37 [1.16; 2.52] (p=0.003). CFB increased level was detected in both groups, but in the C3-GP group it was significantly lower than in the aHUS group - 275.1 [222.1; 356.6] vs 438.7 [323.3; 449.3] (p=0.010). C3a, C5a and MAC levels were increased in both groups, but the maximum was in the C3-GP group, and the MAC level in the C3-GP group was 2 times higher than that in aHUS, and these differences reached statistical significance - 123 555±6686 vs 5603±1294 (p=0.036). CFH and CFD levels was increased in both groups, but their highest values was in the aHUS group. CONCLUSION: Alternative complement pathway activation signs were present in both groups of patients with complement-mediated nephropathies, regardless the stage of the disease. In C3-GP, alternative complement pathway activation was more pronounced than in aHUS after the relief of an acute episode of thrombotic microangiopathy.


Subject(s)
Atypical Hemolytic Uremic Syndrome , Kidney Diseases , Thrombotic Microangiopathies , Humans , Atypical Hemolytic Uremic Syndrome/diagnosis , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/etiology , Immunologic Factors
2.
Ter Arkh ; 92(6): 105-116, 2020 Jul 09.
Article in Russian | MEDLINE | ID: mdl-33346503

ABSTRACT

This review devoted to the nephrotic syndrome (NS) subsequent thrombotic outcomes. The pathogenesis of hypercoagulation disorders that cause venous and arterial vascular system thrombosis are studied. Discussed procoagulant and anticoagulant mechanisms imbalance due to the anticoagulants natural urinal loss, affected by disfunction of the glomerular filter selective permeability, leading to high molecular weight liver-derived proteins (at least of the albumin size) leakage, fibrinolysis depression, excessive liver synthesis of plasma clotting cascade factors and platelet activation. Presented new data on the thrombogenesis at NS concerning the role of endothelial microparticles with high prothrombogenic activity that go from damaged glomerulus endothelial capillary cells into the systemic circulation, which can turn the local renal hypercoagulation (concomitant to the kidney immune inflammation process) into the generalized, working towards the thrombosis development. The most frequent adverse variants of arterial and venous thromboses are studied, specified their basic and general risk factors, as well as individual, varying in different patients. Indications and prophylactic anticoagulant therapy regimen and thrombosis treatment duration in patients with NS are discussed. It also stressed that the decision on time and method of anticoagulant therapy for a NS patients is still a challenge for healthcare providers.


Subject(s)
Nephrotic Syndrome , Thromboembolism , Thrombosis , Anticoagulants , Humans , Kidney Glomerulus , Nephrotic Syndrome/drug therapy
3.
Ter Arkh ; 90(6): 28-34, 2018 Jun 20.
Article in English | MEDLINE | ID: mdl-30701901

ABSTRACT

AIM: Analysis of clinical manifestations, course and outcomes of obstetric aHUS. MATERIALS AND METHODS: 45 patients with aHUS development during pregnancy or immediately after childbirth were observed between 2011 and 2017, age from 16 to 42 years. RESULTS: All patients had AKI (serum creatinine 521,5±388,0 µmol/l, oliguria or anuria that required initiation of hemodialysis). 93.3% pts had extrarenal manifestations of TMA with the development of multiple organ failure (MOF). The mean number of damage organs was 3,7±1,2. In all patients, the development of aHUS was preceded by obstetric complications, surgery, infection, etc. In the outcome: 53.4% women showed complete recovery of renal function, 11.1% developed CKD 4-5 stages, 35.5% had dialysis-dependent end-stage renal failure (ESDR). Maternal mortality was 23.9%. Perinatal mortality was 32.6%. The early start of eculizumab treatment (within 1-2 weeks from the onset of aHUS), compared with therapy start after 3 weeks, increased the chances of favorable outcome for mother in 5.33 times, and the chances for normalization of renal function in 48.7 times. CONCLUSION: Obstetric aHUS is characterized by the development of AKI in 100% of cases. In most patients, the obstetric aHUS occurs with the development of MOF. Timely diagnosis of aHUS and immediate treatment by eculizumab allows not only to save the life of patients, but also completely restore their health.


Subject(s)
Acute Kidney Injury , Atypical Hemolytic Uremic Syndrome , Kidney Failure, Chronic , Pregnancy Complications , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Atypical Hemolytic Uremic Syndrome/complications , Creatinine , Female , Humans , Male , Pregnancy , Renal Dialysis
4.
Ter Arkh ; 89(6): 69-77, 2017.
Article in Russian | MEDLINE | ID: mdl-28745692

ABSTRACT

AIM: To compare the clinical manifestations membranoproliferative glomerulonephritis (MPGN) in its idiopathic variant, lupus nephritis (LN), and C3 glomerulopathy (C3-GP), by comparing them with changes in the complement system. SUBJECTS AND METHODS: The clinic of nephrology followed up 42 patients with different types of MPGN in 2013 to 2015. The study included 35 patients divided into 3 groups: 1) 8 patients with C3-GP, 2) 13 with idiopathic MPGN; 3) 14 with Class IV LN. The investigators studied the blood and urine levels of components and markers for activation of the classical and alternative pathways (C3 and C4, С3а, C5a, CFH, CFB, and CFD) of the terminal complement complex (TCC). RESULTS: The detection rate of C3-GP was 19%. The patients with C3-GP were noted to have the lowest blood concentration of S3 and the highest urinary level of С3а, C5a, TCC, CFH, CFB, and CFD. C3 nephritic factor was detected in 2 patients from the C3-GP (dense deposit disease) group. CONCLUSION: Alternative complement pathway dysregulation caused by genetic or autoimmune factors plays a leading role in the pathogenesis of C3-GP.


Subject(s)
Complement C3/metabolism , Complement System Proteins/metabolism , Glomerulonephritis, Membranoproliferative , Lupus Nephritis , Adult , Complement C3/urine , Complement System Proteins/urine , Female , Glomerulonephritis, Membranoproliferative/blood , Glomerulonephritis, Membranoproliferative/urine , Humans , Lupus Nephritis/blood , Lupus Nephritis/urine , Male
5.
Vestn Ross Akad Med Nauk ; 72(1): 42-52, 2017.
Article in Russian | MEDLINE | ID: mdl-29308852

ABSTRACT

Background: The role of the alternative complement pathway (AP) abnormalities in the pathogenesis of aHUS is well studied. Clinical and morphological manifestations of atypical HUS and catastrophic APS are often similar. However, studies on the state of AP in patients with CAPS are virtually absent. Aims: The aim of our study was to assess the state of AP in patients with CAPS and aHUS. Patients and methods: The study enrolled 67 patients (pts) with a diagnosis of CAPS (28 pts) and aHUS (39 pts). Studies of the complement system are made of 10 pts with CAPS and 20 aHUS. Factor H, I, B, D content, functional activity of factor H, and complement components C3, C4 was determined in serum by ELISA kit. Results: Patients with CAPS and aHUS showed similar changes in complement biomarkers. The factor H level in the serum was significantly higher than the standard value. However, the specific activity of factor H reduced, mean rate 59% for aHUS and 26% for CAPS. The median value of factor D was twice higher than the normal range in both groups, indicating the activation of the AP. Conclusions: There are indications of an AP activation not only in pts with aHUS but in CAPS pts too. We suppose that the activity of factor H is a more sensitive indicator of complement system changes than factor H level. Patients with CAPS and aHUS have similar clinical and laboratory characteristics. However, CAPS is more severe, with the involvement of a larger number of vascular beds. Perhaps this is due to the double damaging effects on the endothelium ­ of antiphospholipid antibodies (aPL) and activated complement. So we hypothesize that CAPS can be called aPL-mediated TMA in pts with a complement system defect.


Subject(s)
Antiphospholipid Syndrome , Atypical Hemolytic Uremic Syndrome , Complement Factor H , Complement System Proteins , Thrombotic Microangiopathies/metabolism , Adult , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/metabolism , Antiphospholipid Syndrome/physiopathology , Atypical Hemolytic Uremic Syndrome/diagnosis , Atypical Hemolytic Uremic Syndrome/metabolism , Atypical Hemolytic Uremic Syndrome/physiopathology , Complement Factor H/analysis , Complement Factor H/metabolism , Complement Pathway, Alternative , Complement System Proteins/analysis , Complement System Proteins/metabolism , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Female , Humans , Male , Statistics as Topic
6.
Ter Arkh ; 86(6): 30-7, 2014.
Article in Russian | MEDLINE | ID: mdl-25095653

ABSTRACT

AIM: To investigate alterations of the complement system in patients with catastrophic antiphospholipid syndrome (CAPS). SUBJECTS AND METHODS: Four patients (2 men aged 23 and 40 years and 2 women aged 39 and 58 years) diagnosed as having CAPS, including 3 patients with systemic lupus erythematosus and secondary antiphospholipid syndrome (APS) and 1 patient with primary APS, were examined. The activity of the complement components C1-C5 and total hemolytic activity were determined in all the patients at the moment of an acute episode and in 1 patient after treatment. RESULTS: The activity of the studied complement components and total hemolytic complement activity proved to be significantly decreased in all the patients. That of complement components recovered after treatment using fresh frozen plasma. The possibility and mechanisms of complement system activation in the patients with CAPS are discussed. CONCLUSION: The preliminary results obtained by the examination of few cases may lead to the conclusion that the complement system may be involved in the development of CAPS.


Subject(s)
Antiphospholipid Syndrome/blood , Complement System Proteins/biosynthesis , Lupus Erythematosus, Systemic/blood , Adult , Antiphospholipid Syndrome/etiology , Antiphospholipid Syndrome/therapy , Catastrophic Illness , Complement System Proteins/metabolism , Female , Humans , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Plasma , Plasma Exchange/methods , Treatment Outcome , Young Adult
7.
Ter Arkh ; 81(8): 30-6, 2009.
Article in Russian | MEDLINE | ID: mdl-19799197

ABSTRACT

AIM: To characterize the course and clinicomorphological features of chronic glomerulonephritis (CGN) in patients with genetic thrombophilia. MATERIAL AND METHODS: A clinical picture and evidence on renal biopsy from 25 patients (12 females, mean age 32 +/- 12 years and 13 males, mean age 36 +/- 8.8 years) admitted to hospital with diagnosis of chronic glomerulonephritis were analysed. Mean duration of renal problem to the moment of biopsy was 37.6 +/- 39 months. Renal end point was stable rise of Scr > 1.4 mg/dl for 6 months. Polymerase chain reaction defined polymorphisms of the genes MTHFR C677T; PTG G20210A; FV Leiden G1691A; FGB G455A; ITGB3 T176C L33P; PAI-1 4G/5G 675. RESULTS: Mutation in one gene was detected in 24% patients, a multigenic form of thrombophilia--in 76% patients. Morphologically, all the patients' renal tissue had the signs of thrombotic microangiopathy (TMA), 8 patients had a combination of acute and chronic TMA. TMA was the only histological sign of nephropathy in 3 (13%) patients, the rest patients showed TMA combination with different morphological variants of CGN. Sclerotic alterations were most severe in combined carriage of the alleles 4G PAI-1 and T MTHFR. A correlation was found between the renal end point and number of mutant alleles (r = 0.6, p < 0.05), the presence of allele 4G (r = 0.46, p = 0.05) and interstitial sclerosis (r = 0.5, p = 0.05). CONCLUSION: Hereditary thrombophilia promotes induction of nephrosclerosis leading to activation of intraglomerular blood clotting which contributes to CGN progression. Patients with genetic thrombophilia may develop acute TMA as the only variant of renal damage.


Subject(s)
Glomerulonephritis/pathology , Kidney/pathology , Thrombophilia/genetics , Adolescent , Adult , Biopsy , Blood Coagulation Factors/genetics , Chronic Disease , Female , Glomerular Filtration Rate , Glomerulonephritis/etiology , Humans , Hypertension/complications , Hypertension/etiology , Hypertension/pathology , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Middle Aged , Mutation , Polymorphism, Genetic , Thrombophilia/complications , Thrombophilia/pathology , Thrombotic Microangiopathies/complications , Thrombotic Microangiopathies/genetics , Thrombotic Microangiopathies/pathology , Young Adult
9.
Farmakol Toksikol ; 45(6): 71-5, 1982.
Article in Russian | MEDLINE | ID: mdl-6891342

ABSTRACT

Experiments on rabbits have shown that caffeine (10 mg/kg), ethimizol (10 mg/kg) and particularly bemegride (5 mg/kg) increase the blood adrenaline and noradrenaline content up to the level characteristic for intact animals under acute ethanol poisoning (2.5 g/kg per os). This effect has been found to be more remarkable on repeated administration. The shifts in the serotonin content are inconsistent in this case.


Subject(s)
Alcoholic Intoxication/blood , Amines/blood , Alcoholic Intoxication/drug therapy , Animals , Bemegride/administration & dosage , Blood Glucose/analysis , Caffeine/administration & dosage , Epinephrine/blood , Ethanol/blood , Etimizol/administration & dosage , Humans , Male , Norepinephrine/blood , Rabbits , Serotonin/blood , Time Factors
10.
Farmakol Toksikol ; 43(2): 202-5, 1980.
Article in Russian | MEDLINE | ID: mdl-6108235

ABSTRACT

It was shown in experiments on rabbits that under acute alcohol poisoning of medium degree, repeated administration of caffeine (10 mg/kg) and bemegrid in particular (5 mg/kg) promotes aerobization of the oxidative processes and mobilizes the respiratory mechanism of metabolic acidosis compensation. Under these conditions, ethimizol (10 mg/kg) stimulates the respiratory center and promotes (to a less measure) aerobization of the metabolic processes in tissues and ethanol elimination.


Subject(s)
Alcoholic Intoxication/metabolism , Central Nervous System Stimulants/administration & dosage , Acidosis/drug therapy , Acidosis/metabolism , Alcoholic Intoxication/drug therapy , Animals , Bemegride/administration & dosage , Caffeine/administration & dosage , Drug Evaluation, Preclinical , Ethanol/metabolism , Etimizol/administration & dosage , Humans , Male , Rabbits , Time Factors
11.
Farmakol Toksikol ; 41(3): 274-9, 1978.
Article in Russian | MEDLINE | ID: mdl-26595

ABSTRACT

Tests conducted on rabbits in a state of acute ethanol poisoning (2.5 g/kg per os) of a medium degree demonstrated that caffein (10 mg/kg) and bemegride (5 mg/kg) introduced one time intravenously at the height of alcoholic intoxication raise the activity of aerobic oxidative processes, but fail to eliminate metabolic acidosis and do not accelerate the excretion of ethanol. Unlike caffein, bemegride shows a tendency toward respiratory compensation of metabolic acidosis and lowers the activity of the alcohol-dehydrogenase.


Subject(s)
Alcoholic Intoxication/drug therapy , Central Nervous System Stimulants/therapeutic use , Acid-Base Equilibrium/drug effects , Acidosis/drug therapy , Alcoholic Intoxication/metabolism , Animals , Bemegride/therapeutic use , Caffeine/therapeutic use , Drug Evaluation, Preclinical , Humans , Male , Rabbits , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...